Safety and Efficacy of NRT6008 Administered in Combination With Chemotherapy in Patients With Unresectable Locally Advanced Pancreatic Carcinoma (LAPC)

NCT07555587 | Not Yet Recruiting Phase 1

• 1 other identifier: NRTPacAU-1
• Study Type: interventional
• Target: 10
• Locations: 1 country
• Sites: 1

Brief Summary

This is a phase Ib, open-label study to evaluate safety and efficacy of NRT6008 in combination with standard-of-care chemotherapy in patients with unresectable Locally Advanced Pancreatic Carcinoma (LAPC).

Conditions

Unresectable Locally Advanced Pancreatic Carcinoma

Keywords

Yttrium-90; Endoscopic ultrasound-guided fine-needle injection; Locally Advanced Pancreatic Carcinoma

Outcome Measures

Primary Outcomes (1)

• Adverse events (AE) and severe adverse events (SAE)

  Properties, incidence, nature, and severity of adverse events (AEs) and serious adverse events (SAEs) per Common Terminology Criteria for Adverse Events (CTCAE) v6.0, abnormal laboratory parameters, vital signs, physical examinations, and electrocardiogram (ECG) results

  Through study completion, an average of 18 months

Secondary Outcomes (5)

• Objective response rate (ORR)

  Through study completion, an average of 18 months

• Duration of response (DOR)

  Through study completion, an average of 18 months

• Progression-free survival (PFS)

  Through study completion, an average of 18 months

• Overall survival (OS)

  Through study completion, an average of 18 months

• Surgical resection rate (R0+R1 resection)

  Through study completion, an average of 18 months

Other Outcomes (2)

• Concentration of tumor biomarkers

  Through study completion, an average of 18 months

• Numeric rating scale (NRS) of pain

  Through study completion, an average of 18 months

Study Arms (1)

NRT6008 Injection

EXPERIMENTAL

In this study, participants shall receive NRT6008 injection in combination with chemotherapy.

Device: NRT6008 Injection; Drug: Systematic chemotherapy

Interventions

NRT6008 Injection DEVICE

In this study, all participants shall receive NRT6008 injection (for 200 Gy tumour tissue absorbed dose).

NRT6008 Injection

Systematic chemotherapy DRUG

Participants will be assigned to receive chemotherapy (GN or (m)FOLFIRINOX) at the Investigator's discretion and in accordance with institutional practice. Chemotherapy will be initiated in Cycle 1. The investigational device, NRT6008 Injection, will be administered 10 days (±3 days) after completion of the tumour assessment in Cycle 1. Participants will then receive Cycle 2 Day 1 chemotherapy 7 days (±1 day) following NRT6008 administration. The Investigator-assigned chemotherapy regimen will continue throughout the study until the occurrence of disease progression, intolerance to chemotherapy, death, loss to follow-up, or determination of eligibility for surgical resection (including R0 or R1 resection), whichever occurs first.

NRT6008 Injection

Eligibility Criteria

• Age: 18 Years - 85 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Aged ≥18 and ≤85 years of age and able to understand and sign the informed consent form (ICF).
• Histopathological or cytologically confirmed diagnosis of ductal adenocarcinoma of the pancreas.
• Deemed by the Investigator to have unresectable locally advanced pancreatic cancer.
• Eastern Cooperative Oncology Group (ECOG) performance status score ≤ 1.
• Life expectancy of at least 3 months in the opinion of the Investigator.
• Must have only one measurable target radiologically confirmed lesion in the pancreas according to RECIST 1.1, with the longest diameter of ≤ 6 cm and the shortest diameter of ≥ 2 cm (based on baseline imaging).
• Adequate organ and marrow function as defined by the following criteria:
• Renal function: Blood creatinine ≤ 1.5 × the upper limit of normal (ULN), or eGFR ≥ 60 mL/min \[by a clinically validated calculator such as Modification of diet in renal disease (MDRD) formula\];
• Liver function: Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≤ 3×ULN; serum total bilirubin ≤ 1.5×ULN\*
• \*For study participants with recent biliary obstruction treated by drainage (e.g. stent), serum total bilirubin of \> 1.5×ULN will be accepted for study entry provided that serial levels demonstrate clear improvement. In addition, chemotherapy should not be commenced until serum bilirubin is ≤ 1.5×ULN.
• Bone marrow function (without transfusion or treatment with granulocyte-colony stimulating factor (G-CSF), human thrombopoietin (TPO), or TPO receptor agonists (TPO-RAs) within 14 days before signing the ICF: Neutrophil count ≥ 1.5×10\^9/L, haemoglobin ≥ 90 g/L, platelets≥ 100×10\^9/L;
• Coagulation function: International normalised ratio (INR) or prothrombin time (PT) ≤ 1.5 × ULN and activated partial thromboplastin time (APTT) ≤ 1.5 × ULN.
• Women of childbearing potential (WOCBP) must have a negative serum beta-human chorionic gonadotropin (β-hCG) test and must not be breastfeeding. WOCBP are defined as those who are not surgically sterile or post-menopausal. Female participants will be considered post-menopausal if they have been amenorrhoeic for 12 months without an alternative medical cause.
• WOCBP and male participants must agree to use a highly effective method of contraception after signing the ICF, during the study, and for 12 months after administration of NRT6008.
• Male participants who are able to father a child must agree to avoid impregnating a partner and to adhere to a highly effective method of contraception during the study and for 12 months after the administration of NRT6008. All male participants must agree to not donate sperm during the study and for at least 12 months after NRT6008 administration.

You may not qualify if:

• Allergic to the investigational device NRT6008 Injection or any of its components.
• Participants who are deemed by the Investigator to be clinically inappropriate for treatment with either standard-of-care chemotherapy regimen (Regimen group A or Regimen group B).
• Prior anti-tumour therapy for pancreatic carcinoma, including but not limited to chemotherapy, radiotherapy, targeted therapy, immunotherapy, etc.
• Contraindications to anaesthesia.
• Participants who have any other known, active malignancy, except for treated cervical intraepithelial neoplasia, or nonmelanoma skin cancer in the past 5 years. Participants with a history of malignancies of low recurrence potential who have received curative-intent therapy may be approved on a case-by-case basis in discussion with the study Sponsor, if it is determined not to put the participant at an increased risk of adverse device effects and/or interfere with the integrity of study outcome.
• Presence or suspicion of distant metastasis, including non-regional lymph nodes, on imaging.
• Pregnant or lactating women.
• The participant is considered by the Investigator to be at an unacceptably high risk for the EUS-FNI procedure, or the procedure is deemed technically infeasible based on clinical judgment.
• Radiation injury to the stomach, duodenum, or peritoneum, and/or other conditions that put the participant at an increased risk of intervention-related toxicities such as certain types of prior abdominal surgery that significantly alters the upper abdomen anatomy, by Investigator judgment.
• Presence of uncontrolled or unstable chronic medical conditions despite appropriate treatment (e.g., hypertension, diabetes mellitus), or any medical condition that, in the Investigator's judgment, would compromise participant safety or study participation, or interfere with the integrity of study outcomes.
• History of acute pancreatitis, severe gastrointestinal haemorrhage, a severe cardio- or cerebrovascular event (including but not limited to stroke, unstable angina pectoris) within 6 months before the first dose of chemotherapy regimen, or presence of an active infection requiring systemic treatment within 2 weeks prior to first dose of chemotherapy regimen.
• Participation in any other clinical study within 1 month before the first dose of the chemotherapy regimen.
• Positive status for human immunodeficiency virus (HIV).
• For participants positive for HBsAg and/or HBcAb, hepatitis B virus (HBV) DNA must be undetectable or \<500 IU/mL to be eligible. Antiviral therapy must be maintained throughout the study period, where clinically applicable.
• Participants who are positive for hepatitis C virus (HCV) antibody must have undetectable HCV RNA to be eligible for enrolment.

Sponsors & Collaborators

• NRT MedTech Australia Pty Ltd: lead

Study Sites (1)

Royal Adelaide Hospital

Adelaide, Australia

Location

Central Study Contacts

Nam Nguyen

CONTACT

0422113598; QUOCNAM.NGUYEN@SA.GOV.AU

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 16, 2026
• First Posted: April 29, 2026
• Study Start (Estimated): September 1, 2026
• Primary Completion (Estimated): August 1, 2028
• Study Completion (Estimated): June 1, 2029
• Last Updated: April 29, 2026

Record last verified: 2026-04

Data Sharing

• IPD Sharing: Will not share

Locations

AU (1)